|Articles|June 8, 2020
Managing the COVID-19 Drug Safety Response
Author(s)MyMeds&Me
Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.
Related Content
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Your Questions Answered: The Biggest Pharma and Biotech Stories This Week
3
What's Next for Compounded Peptides: Q&A with Nate Hill
4
Pharmaceutical Executive Daily: FDA Approves Zanvastro
5